<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043782</url>
  </required_header>
  <id_info>
    <org_study_id>CP241</org_study_id>
    <nct_id>NCT02043782</nct_id>
  </id_info>
  <brief_title>Investigation of a New 1-piece Convex Ostomy Product</brief_title>
  <official_title>Investigation of a New 1-piece Convex Ostomy Product in Subjects With Ileostomy and Colostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigation was to investigate the performance and safety of a new ostomy
      product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of Leakage</measure>
    <time_frame>14 +/- 3 days</time_frame>
    <description>The degree of leakage is investigated on a 32-point scale (including 0 for no leakage). O represents no leakage and 32 represents the worst leakage.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Stoma Ileostomy</condition>
  <condition>Stoma Colostomy</condition>
  <arm_group>
    <arm_group_label>First Coloplast Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
First subjects are allocated to Coloplast Test; Secondly to either
Own product (baseline)
Competitor soft convex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Competitor soft convex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
First subjects are allocated to Competitor soft convex; Secondly to either
Own product (baseline)
Coloplast Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Own product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.
First subjects are allocated to Own product; Secondly to either
Coloplast Test
Competitor soft convex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coloplast Test</intervention_name>
    <description>Newly developed 1-piece convex ostomy product</description>
    <arm_group_label>First Coloplast Test</arm_group_label>
    <arm_group_label>First Competitor soft convex</arm_group_label>
    <arm_group_label>First Own product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Own product</intervention_name>
    <description>The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.</description>
    <arm_group_label>First Coloplast Test</arm_group_label>
    <arm_group_label>First Competitor soft convex</arm_group_label>
    <arm_group_label>First Own product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Competitor soft convex</intervention_name>
    <description>A commercially available soft convex product</description>
    <arm_group_label>First Coloplast Test</arm_group_label>
    <arm_group_label>First Competitor soft convex</arm_group_label>
    <arm_group_label>First Own product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 18 years of age and have full legal capacity.

          -  Have had an ileostomy/colostomy for more than 3 months

          -  Have used a 1-piece flat ostomy product for the last 1 month

          -  Has given written Informed Consent and signed the letter of authority

          -  Have an ileostomy or colostomy with a diameter of 33 mm or less

          -  Has experienced leakage (seeping) under the baseplate at least three times during the
             last two weeks

          -  Are evaluated to be suitable for a soft convex product

          -  If having a colostomy: changes their product on average 2 times pr. 24h or more

          -  Currently uses a bag of size medi/midi or maxi

        Exclusion Criteria:

          -  Have a loop ostomy (also called double-barrel or ostomy with two outlets).

          -  Are pregnant or breastfeeding

          -  Currently receiving or have within the past 2 month received radio- and/or
             chemotherapy

          -  Currently receiving or have within the past month received systemic or local steroid
             treatment in the peristomal area

          -  Currently suffering from peristomal skin problems (i.e. bleeding or broken skin).

          -  Known hypersensitivity toward any of the test products

          -  Participating in other interventional clinical investigations or have previously
             participated in this investigation

          -  Use irrigation during the investigation (flush the intestine with water)

          -  Have a fistula in the peristomal area or less than 2 cm from the edge of the baseplate

          -  If subject has a colostomy: empties the bag
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birte P Jakobsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TFS</name>
      <address>
        <city>SÃ¸borg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <results_first_submitted>November 4, 2015</results_first_submitted>
  <results_first_submitted_qc>November 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2015</results_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test - Competitor - Own</title>
          <description>The subjects were randomized into six possible treatment groups:
The order of test products for this group was:
Coloplast test product Competitor soft convex product Own product
Coloplast Test: Newly developed 1-piece convex ostomy product
Own product: The subject's own product was used as baseline performance in this investigation. The products are commercially available on the market, and are products manufactured by manufactures who produce convex ostomy products, i.e. Coloplast, Convatec, Dansac, B. Braun, Hollister and more.
Competitor soft convex: A commercially available soft convex product</description>
        </group>
        <group group_id="P2">
          <title>Competitor - Own - Test</title>
          <description>The subjects were randomized into six possible treatment groups:
The order of test products for this group was:
Competitor soft convex product Own product Coloplast test product
Coloplast Test: Newly developed 1-piece convex ostomy product
Own product: The subjectÂ´s own product was used as baseline performance in this investigation. The products are commercially available on the market, and are products manufactured by manufactures who produce convex ostomy products, i.e. Coloplast, Convatec, Dansac, B. Braun, Hollister and more.
Competitor soft convex: A commercially available soft convex product</description>
        </group>
        <group group_id="P3">
          <title>Own - Test - Competitor</title>
          <description>The subjects were randomized into six possible treatment groups:
The order of test products for this group was:
Own product Coloplast test product Competitor soft convex product
Coloplast Test: Newly developed 1-piece convex ostomy product
Own product: The subjectÂ´s own product was used as baseline performance in this investigation. The products are commercially available on the market, and are products manufactured by manufactures who produce convex ostomy products, i.e. Coloplast, Convatec, Dansac, B. Braun, Hollister and more.
Competitor soft convex: A commercially available soft convex product</description>
        </group>
        <group group_id="P4">
          <title>Competitor - Test - Own</title>
          <description>The subjects were randomized into six possible treatment groups:
The order of test products for this group was:
Competitor soft convex product Coloplast test product Own product
Coloplast Test: Newly developed 1-piece convex ostomy product
Own product: The subjectÂ´s own product was used as baseline performance in this investigation. The products are commercially available on the market, and are products manufactured by manufactures who produce convex ostomy products, i.e. Coloplast, Convatec, Dansac, B. Braun, Hollister and more.
Competitor soft convex: A commercially available soft convex product</description>
        </group>
        <group group_id="P5">
          <title>Own - Competitor - Test</title>
          <description>The subjects were randomized into six possible treatment groups:
The order of test products for this group was:
Own product Competitor soft convex product Coloplast test product
Coloplast Test: Newly developed 1-piece convex ostomy product
Own product: The subjectÂ´s own product was used as baseline performance in this investigation. The products are commercially available on the market, and are products manufactured by manufactures who produce convex ostomy products, i.e. Coloplast, Convatec, Dansac, B. Braun, Hollister and more.
Competitor soft convex: A commercially available soft convex product</description>
        </group>
        <group group_id="P6">
          <title>Test - Own - Competitor</title>
          <description>The subjects were randomized into six possible treatment groups:
The order of test products for this group was:
Coloplast test product Own product Competitor soft convex product
Coloplast Test: Newly developed 1-piece convex ostomy product
Own product: The subjectÂ´s own product was used as baseline performance in this investigation. The products are commercially available on the market, and are products manufactured by manufactures who produce convex ostomy products, i.e. Coloplast, Convatec, Dansac, B. Braun, Hollister and more.
Competitor soft convex: A commercially available soft convex product</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6">One subject discontinued due to an adverse event while testing own product</participants>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Pooled data from all arms.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Degree of Leakage</title>
        <description>The degree of leakage is investigated on a 32-point scale (including 0 for no leakage). O represents no leakage and 32 represents the worst leakage.</description>
        <time_frame>14 +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast Test Product</title>
            <description>Subjects testing Coloplast test product</description>
          </group>
          <group group_id="O2">
            <title>Own Product</title>
            <description>Subjects testing own product</description>
          </group>
          <group group_id="O3">
            <title>Competitor Soft Convex</title>
            <description>Subjects testing Competitor Soft Convex</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Leakage</title>
          <description>The degree of leakage is investigated on a 32-point scale (including 0 for no leakage). O represents no leakage and 32 represents the worst leakage.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Baseplates</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="552"/>
                <count group_id="O2" value="759"/>
                <count group_id="O3" value="612"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="4.8"/>
                    <measurement group_id="O2" value="4.8" spread="5.7"/>
                    <measurement group_id="O3" value="2.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AE were reported throughout the investigation, up to 5 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coloplast Test Product</title>
          <description>Adverse events reported by subjects testing Coloplast test product</description>
        </group>
        <group group_id="E2">
          <title>Own Product</title>
          <description>Adverse events reported by subjects testing own product</description>
        </group>
        <group group_id="E3">
          <title>Competitor Soft Convex</title>
          <description>Adverse events reported by subjects testing Competitor soft convex</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <description>Unlikely related to the product</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>control of fistula, pain after control of fistula, constipation, sub ileus</sub_title>
                <description>unlikely or not related to the product</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <description>not related to product</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza/ cold/ sore throat, Pneumonia, vomiting, infected wounds</sub_title>
                <description>all AEs except one were unlikely or not related to the product. One AE (wound due to lower corner at hideaway scratching against leg) was definitely related to the product.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache, pain in right hand</sub_title>
                <description>unlikely and not related to product</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Peristomal skin irritation/ broken skin/ stomal bleeding</sub_title>
                <description>Definitely, probably or possibly related to the product</description>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" events="32" subjects_affected="21" subjects_at_risk="37"/>
              </event>
              <event>
                <description>Its written in the AE description: drainage is something mess, due to missing flap which is on the coloplast product.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Gash on the riight Tibia (tipped on bike)</sub_title>
                <description>not related to product</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <description>unlikely related to product</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Coloplast A/S</organization>
      <phone>+45 4911 1395</phone>
      <email>dkbir@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

